Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc

Exelixis focuses on oncology, developing treatments and innovative therapies for cancer management. The company is engaged in research and development for potential cancer therapies across various modalities and mechanisms of action.

COM:EXELIXIS